期刊
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE
卷 1, 期 3, 页码 214-226出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jaip.2013.03.012
关键词
Allergic rhinitis; Pediatrics; Specific immunotherapy; Intranasal corticosteroids; Antihistamines; Leukotriene modifiers
资金
- Merck
- Teva
- GlaxoSmithKline
- Sunovian
- Oxford Therapeutics
- Ono
- Britannia
- Meda
- Stallergenes
- Greer Laboratories
- Novartis
- Sunovion
- Istavision
BACKGROUND: Allergic rhinitis (AR) is a common pediatric problem that significantly affects sleep, learning, performance, and quality of life. In addition, it is associated with significant comorbidities and complications. OBJECTIVE: The aim was to provide an update on the epidemiology, comorbidities, pathophysiology, current treatment, and future direction of pediatric AR. METHODS: Literature reviews in each of these areas were conducted, and the results were incorporated. RESULTS: The prevalence of AR is increasing in the pediatric population and is associated with significant morbidity, comorbidities, and complications. The mainstay of current treatment strategies includes allergen avoidance, pharmacotherapy, and allergen specific immunotherapy. CONCLUSIONS: In the future, diagnosis will be improved by microarrayed recombinant allergen testing and therapy will be expanded to include emerging treatments such as sublingual immunotherapy and combination products. (C) 2013 American Academy of Allergy, Asthma & Immunology
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据